Type 1 Diabetes
Conditions
Brief summary
This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm that is built into the 670G insulin pump is safe as part of the overall system.
Detailed description
The study will proceed as follows: Run-in Period: A total of up to 150 subjects (age 14 - 75) will be enrolled at up to 10 investigational centers (9 in the US, 1 in the Europe, Middle East and Africa (EMEA) region) in order to reach 100 subjects who will complete the HCL study. The 2-week run-in period will be used to allow subjects to become familiar with new study devices. During the two week run-in period subjects will be using the Study Pump (670G) with the Sensor Augmented Pump function only activated (i.e. SmartGuard OFF and HCL OFF). Study Period - At Home: Following the two week run-in period using the Study Pump (670G), all subjects will participate in a 3-month study period. Subjects will be required to have a companion with them during the night for the duration of the study period. Companions will need to be under the same roof, but not necessarily in the same bedroom. During the Hotel stay where subjects are monitored closely, the presence of a companion is not necessary. Study Period - Hotel Study Subjects will participate in a Hotel study (6 days, 5 nights), with the remainder of the study period to be spent at home. All subjects will undergo daytime and nighttime Frequent Sample Testing (FST) for approximately 24 hours during the Hotel study with YSI or i-STAT® used as a reference value. With respect to meals, subjects will be allowed to eat as they normally do. Continued Access Program Subjects will be given the opportunity to extend use of their study devices for a period of 3 years. If subjects choose to participate in the continuation period, they will retain the study devices at the end of study period visit or receive them back in the event they have been returned to study staff already. During the continuation period, subjects will come in for office visits every 3 months. At each of the quarterly visits, subjects will be asked about the occurrence of adverse events and device complaints.
Interventions
DEVICEInsulin Pump
Closed Loop Algorithm
Sponsors
Medtronic Diabetes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Is age 14 - 75 years at time of screening 2. Has a clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis 3. Is willing to participate in a hotel study for the specified duration of hotel stay. 4. Must have companion who will sleep in the same dwelling place every night during the study period and should also be able to call the subject daily in the event the subject is traveling. 5. Is willing to perform ≥ 4 finger stick blood glucose measurements daily 6. Is willing to perform required sensor calibrations 7. Is willing to wear the system continuously throughout the study 8. Has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central Lab) at time of screening visit 9. Has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range. 10. Pump therapy for greater than 6 months prior to screening (with or without CGM experience) 11. Is willing to upload data from the study pump, must have Internet access and a computer system that meets the requirements for uploading the study pump 12. If subject has celiac disease, it has been adequately treated as determined by the investigator 13. Is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount) * Humalog® (insulin lispro injection) * NovoLog® (insulin aspart) 14. With history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist 15. With 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist Cardiovascular risk factors include: * Age \>35 years * Type 1 diabetes of \>15 years' duration * Presence of any additional risk factor for coronary artery disease * Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria) * Presence of peripheral vascular disease * Presence of autonomic neuropathy 16. With history of cardiovascular event 1 year or more from the time of screening must have a stress test within 6 months prior to screening or during run in period. If subject fails stress test, participation is allowed if there is clearance from a cardiologist 17. Must be able to speak and be literate in English
Exclusion criteria
1. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening: * Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization) * Coma * Seizures 2. Is unable to tolerate tape adhesive in the area of sensor placement 3. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection) 4. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator. 5. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease 6. Is being treated for hyperthyroidism at time of screening 7. Has diagnosis of adrenal insufficiency 8. Has had DKA in the 6 months prior to screening visit. 9. Has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study 10. Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks 11. Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes 12. Currently abusing illicit drugs 13. Currently abusing marijuana. 14. Currently abusing prescription drugs 15. Currently abusing alcohol 16. Using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening 17. Has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator 18. Has elective surgery planned that requires general anesthesia during the course of the study 19. Has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening 20. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation 21. Diagnosed with current eating disorder such as anorexia or bulimia 22. Diagnosed with chronic kidney disease that results in chronic anemia 23. Hematocrit that is below the normal reference range of lab used. 24. On dialysis 25. Serum creatinine of \>2 mg/dL.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in A1C | Baseline and 3 months | There is no statistically powered primary endpoint in this study. However, there will be a descriptive analysis of change in A1C. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Severe Hypoglycemia Events | 3 months | There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis of the number of Severe Hypoglycemia events. |
| Number of Diabetic Ketoacidosis (DKA) Events | 3 months | There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis on number of Diabetic Ketoacidosis (DKA) Event. |
Countries
Israel, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Study Arm All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
Insulin Pump: Closed Loop Algorithm
i-STAT blood testing: Intravenous i-STAT blood testing is used for reference validation
Blood Glucose Meter testing: Frequent finger stick blood glucose testing using a Blood Glucose meter is required | 124 |
| Total | 124 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Study Arm |
|---|---|
| Age, Categorical <=18 years | 22 Participants |
| Age, Categorical >=65 years | 6 Participants |
| Age, Categorical Between 18 and 65 years | 96 Participants |
| Age, Continuous | 37.8 years STANDARD_DEVIATION 16.46 |
| Region of Enrollment Israel | 12 participants |
| Region of Enrollment United States | 112 participants |
| Sex: Female, Male Female | 69 Participants |
| Sex: Female, Male Male | 55 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 124 |
| other Total, other adverse events | 66 / 124 |
| serious Total, serious adverse events | 2 / 124 |
Outcome results
Primary
Change in A1C
There is no statistically powered primary endpoint in this study. However, there will be a descriptive analysis of change in A1C.
Time frame: Baseline and 3 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Study Arm | Change in A1C | -0.5 Percent | Standard Deviation 0.6 |
Secondary
Number of Diabetic Ketoacidosis (DKA) Events
There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis on number of Diabetic Ketoacidosis (DKA) Event.
Time frame: 3 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study Arm | Number of Diabetic Ketoacidosis (DKA) Events | 0 events |
Secondary
Number of Severe Hypoglycemia Events
There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis of the number of Severe Hypoglycemia events.
Time frame: 3 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study Arm | Number of Severe Hypoglycemia Events | 0 events |